ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO001

Effect of the Seraph® 100 Biomimetic Pathogen Adsorbing Device on Inflammatory Biomarkers in 42 COVID-19 Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Kielstein, Jan T., Academic Teaching Hospital Braunschweig, Braunschweig, Germany
  • Dan-Nicolae, Borchina, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
  • Schmidt, Julius, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
Background

Lack of pharmacological treatment options in severely ill hospitalized COVID-19 patients prompted explorations of extracorporeal treatments . The Seraph® 100 Microbind® Affinity filter, remove viruses, including SARS-CoV-2 from the blood. Data from an international registry, from a multicenter evaluation in the US, as well as from several case reports suggest that Seraph® 100 can not only be safely used but it may have an impact on patient centered outcome parameters. As it is unknown whether the effect of the Seraph® 100 in COVID-19 patients is solely based on the removal of the virus or, as suggest by a recent observation, by additionally modulating inflammation, we set out to perform a biomarker study.

Methods

We performed this prospective multicenter observational trial at three tertiary care hospitals in patients being treated with Seraph® 100 for severe COVID-19 between June 2020 and April 2021. Biomarkers were obtained before the tretment as well as 2-4 hours after the treatment. as well as 4 days after the Seraph® 100 treatment. Routine clinical chemistry parameters were performed in the respective clinical chemistry labs using certified methods. For the assessment of the inflammatory markers a Bio-Plex Pro Human Cytokine Screening Panel, 48-Plex #12007283 (Bio-Rad) was used.

Results

From June 1st 2020 to April 1st 2021, 42 patients with COVID-19 treated with the Seraph® 100 in our hospitals could be included in the study. Hemoperfusion treatment was initiated in median 3 days after hospital admission. At beginning of the treatment 41/42 (98%) of patients were in the ICU; 8/42 (19%) needed mechanical ventilation, 3/42 (7%) were on additional ECMO support; 27/42 (64%) needed pressors. Seraph® 100 treatment significantly reduced d-dimer comparing pre-treatment data with data obtained 2-4 hours after treatment
Four days after treatment hemoglobin, LDH, D-dimer, troponin and ferritin were significant reduced. From the interleukin assay IL-1b, IL8, IL-10, IL-13, IL-15, Eotaxin, G-CSF and IP-10 were significantly reduced 2-4 hours after treatment, but not 4 days later. The median hospital stay was 20 days. After 3 months 20/42 (48%) of patients had died.

Conclusion

In conclusion, our data show that Seraph® 100 leads to a significant reduction of biomarkers that are either predictive of adverse outcome or the severity COVID-19.